Evidence and implications of pre‐existing humoral cross‐reactive immunity to SARS‐CoV‐2
Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has emerged throughout the world. Building knowledge around Covid‐19 is crucial to devise facts based approaches to respond efficiently against this pandemic. Aim We aimed to investigate pre‐existing humoral cross‐react...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-03-01
|
| Series: | Immunity, Inflammation and Disease |
| Online Access: | https://doi.org/10.1002/iid3.367 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850211271830405120 |
|---|---|
| author | Amandine Mveang Nzoghe Paulin N. Essone Marielle Leboueny Anicet Christel Maloupazoa Siawaya Eliode Cyrien Bongho Ofilia Mvoundza Ndjindji Rotimi Myrabelle Avome Houechenou Selidji Todagbe Agnandji Joel Fleury Djoba Siawaya |
| author_facet | Amandine Mveang Nzoghe Paulin N. Essone Marielle Leboueny Anicet Christel Maloupazoa Siawaya Eliode Cyrien Bongho Ofilia Mvoundza Ndjindji Rotimi Myrabelle Avome Houechenou Selidji Todagbe Agnandji Joel Fleury Djoba Siawaya |
| author_sort | Amandine Mveang Nzoghe |
| collection | DOAJ |
| description | Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has emerged throughout the world. Building knowledge around Covid‐19 is crucial to devise facts based approaches to respond efficiently against this pandemic. Aim We aimed to investigate pre‐existing humoral cross‐reactive immunity to SARS‐CoV‐2. Method We have tested the reactivity against SARS‐CoV‐2 nucleocapsid (N) antigen of sera collected from healthy healthcare volunteers in 2014. We assessed immunoglobulins reactive against SARS‐CoV‐2 N‐antigen using a well‐validated serological platform; Elecsys assay. Results Sera from 32 subjects (out of 135 [23.7%]) were reactive to SARS‐CoV‐2 N‐antigen, suggesting the presence of anti‐SARS‐CoV‐2 N‐antigen antibodies. Conclusion Although the clinical relevance of the observed reactivity can only be speculated and needs to be investigated, the implication of this finding for coronavirus disease 2019 seroepidemiological survey and vaccines' clinical trials is critical. |
| format | Article |
| id | doaj-art-54a8d0a66bde4827a6f684b93be4f3b3 |
| institution | OA Journals |
| issn | 2050-4527 |
| language | English |
| publishDate | 2021-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Immunity, Inflammation and Disease |
| spelling | doaj-art-54a8d0a66bde4827a6f684b93be4f3b32025-08-20T02:09:35ZengWileyImmunity, Inflammation and Disease2050-45272021-03-019112813310.1002/iid3.367Evidence and implications of pre‐existing humoral cross‐reactive immunity to SARS‐CoV‐2Amandine Mveang Nzoghe0Paulin N. Essone1Marielle Leboueny2Anicet Christel Maloupazoa Siawaya3Eliode Cyrien Bongho4Ofilia Mvoundza Ndjindji5Rotimi Myrabelle Avome Houechenou6Selidji Todagbe Agnandji7Joel Fleury Djoba Siawaya8Unité de Recherche et Diagnostics Spécialisé, Service Laboratoire, CHU‐Mère‐Enfant Fondation Jeanne EBORI Libreville GabonCenter de Recherches Médicales de Lambaréné Lambaréné GabonUnité de Recherche et Diagnostics Spécialisé, Service Laboratoire, CHU‐Mère‐Enfant Fondation Jeanne EBORI Libreville GabonUnité de Recherche et Diagnostics Spécialisé, Service Laboratoire, CHU‐Mère‐Enfant Fondation Jeanne EBORI Libreville GabonUnité de Recherche et Diagnostics Spécialisé, Service Laboratoire, CHU‐Mère‐Enfant Fondation Jeanne EBORI Libreville GabonUnité de Recherche et Diagnostics Spécialisé, Service Laboratoire, CHU‐Mère‐Enfant Fondation Jeanne EBORI Libreville GabonUnité de Recherche et Diagnostics Spécialisé, Service Laboratoire, CHU‐Mère‐Enfant Fondation Jeanne EBORI Libreville GabonCenter de Recherches Médicales de Lambaréné Lambaréné GabonUnité de Recherche et Diagnostics Spécialisé, Service Laboratoire, CHU‐Mère‐Enfant Fondation Jeanne EBORI Libreville GabonAbstract Background Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has emerged throughout the world. Building knowledge around Covid‐19 is crucial to devise facts based approaches to respond efficiently against this pandemic. Aim We aimed to investigate pre‐existing humoral cross‐reactive immunity to SARS‐CoV‐2. Method We have tested the reactivity against SARS‐CoV‐2 nucleocapsid (N) antigen of sera collected from healthy healthcare volunteers in 2014. We assessed immunoglobulins reactive against SARS‐CoV‐2 N‐antigen using a well‐validated serological platform; Elecsys assay. Results Sera from 32 subjects (out of 135 [23.7%]) were reactive to SARS‐CoV‐2 N‐antigen, suggesting the presence of anti‐SARS‐CoV‐2 N‐antigen antibodies. Conclusion Although the clinical relevance of the observed reactivity can only be speculated and needs to be investigated, the implication of this finding for coronavirus disease 2019 seroepidemiological survey and vaccines' clinical trials is critical.https://doi.org/10.1002/iid3.367 |
| spellingShingle | Amandine Mveang Nzoghe Paulin N. Essone Marielle Leboueny Anicet Christel Maloupazoa Siawaya Eliode Cyrien Bongho Ofilia Mvoundza Ndjindji Rotimi Myrabelle Avome Houechenou Selidji Todagbe Agnandji Joel Fleury Djoba Siawaya Evidence and implications of pre‐existing humoral cross‐reactive immunity to SARS‐CoV‐2 Immunity, Inflammation and Disease |
| title | Evidence and implications of pre‐existing humoral cross‐reactive immunity to SARS‐CoV‐2 |
| title_full | Evidence and implications of pre‐existing humoral cross‐reactive immunity to SARS‐CoV‐2 |
| title_fullStr | Evidence and implications of pre‐existing humoral cross‐reactive immunity to SARS‐CoV‐2 |
| title_full_unstemmed | Evidence and implications of pre‐existing humoral cross‐reactive immunity to SARS‐CoV‐2 |
| title_short | Evidence and implications of pre‐existing humoral cross‐reactive immunity to SARS‐CoV‐2 |
| title_sort | evidence and implications of pre existing humoral cross reactive immunity to sars cov 2 |
| url | https://doi.org/10.1002/iid3.367 |
| work_keys_str_mv | AT amandinemveangnzoghe evidenceandimplicationsofpreexistinghumoralcrossreactiveimmunitytosarscov2 AT paulinnessone evidenceandimplicationsofpreexistinghumoralcrossreactiveimmunitytosarscov2 AT marielleleboueny evidenceandimplicationsofpreexistinghumoralcrossreactiveimmunitytosarscov2 AT anicetchristelmaloupazoasiawaya evidenceandimplicationsofpreexistinghumoralcrossreactiveimmunitytosarscov2 AT eliodecyrienbongho evidenceandimplicationsofpreexistinghumoralcrossreactiveimmunitytosarscov2 AT ofiliamvoundzandjindji evidenceandimplicationsofpreexistinghumoralcrossreactiveimmunitytosarscov2 AT rotimimyrabelleavomehouechenou evidenceandimplicationsofpreexistinghumoralcrossreactiveimmunitytosarscov2 AT selidjitodagbeagnandji evidenceandimplicationsofpreexistinghumoralcrossreactiveimmunitytosarscov2 AT joelfleurydjobasiawaya evidenceandimplicationsofpreexistinghumoralcrossreactiveimmunitytosarscov2 |